{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:32:42Z","timestamp":1793680362374,"version":"4.5.1"},"reference-count":115,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1097\/hrp.0000000000000075","type":"journal-article","created":{"date-parts":[[2015,3,6]],"date-time":"2015-03-06T10:17:35Z","timestamp":1425637055000},"page":"63-75","source":"Crossref","is-referenced-by-count":496,"title":["Medication-Assisted Treatment of Opioid Use Disorder"],"prefix":"10.1097","volume":"23","author":[{"given":"Hilary Smith","family":"Connery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-2-20210129","first-page":"1487","article-title":"Vital signs: overdoses of prescription opioid pain relieversUnited States, 1999-2008.","volume":"60","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R5-2-20210129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.annemergmed.2008.07.015","article-title":"The underrecognized toll of prescription opioid abuse on young children.","volume":"53","author":"Bailey","year":"2009","journal-title":"Ann Emerg Med"},{"key":"R6-2-20210129","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jaac.2012.11.014","article-title":"Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS()) System.","volume":"52","author":"Zosel","year":"2013","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R7-2-20210129","doi-asserted-by":"crossref","first-page":"816","DOI":"10.2105\/AJPH.2013.301812","article-title":"Confronting the emerging epidemic of HCV infection among young injection drug users.","volume":"104","author":"Valdiserri","year":"2014","journal-title":"Am J Public Health"},{"key":"R8-2-20210129","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapiestackling the opioid-overdose epidemic.","volume":"370","author":"Volkow","year":"2014","journal-title":"N Engl J Med"},{"key":"R9-2-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cpr.2009.10.006","article-title":"A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction.","volume":"30","author":"Veilleux","year":"2010","journal-title":"Clin Psychol Rev"},{"key":"R10-2-20210129","first-page":"588","article-title":"Diagnosing and treating opioid dependence.","volume":"61","author":"Hill","year":"2012","journal-title":"J Fam Pract"},{"key":"R11-2-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10550887.2012.694598","article-title":"Maintenance medication for opiate addiction: the foundation of recovery.","volume":"31","author":"Bart","year":"2012","journal-title":"J Addict Dis"},{"key":"R13-2-20210129","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00213-006-0571-4","article-title":"Effects associated with double-blind omission of buprenorphinenaloxone over a 98-h period.","volume":"189","author":"Correia","year":"2006","journal-title":"Psychopharmacology"},{"key":"R14-2-20210129","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0024-3205(94)00848-5","article-title":"Alternate-day dosing during buprenorphine treatment of opioid dependence.","volume":"54","author":"Amass","year":"1994","journal-title":"Life Sci"},{"key":"R15-2-20210129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1124\/jpet.113.209478","article-title":"A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.","volume":"348","author":"Tompkins","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"R16-2-20210129","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/978-0-387-73693-8_85","article-title":"Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonistantagonist buprenorphine.","volume":"605","author":"Sarton","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"R17-2-20210129","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.forsciint.2013.01.028","article-title":"A review of methadone deaths between 2001 and 2005 in Victoria, Australia.","volume":"226","author":"Pilgrim","year":"2013","journal-title":"Forensic Sci Int"},{"key":"R18-2-20210129","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","article-title":"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.","volume":"19","author":"McCance-Katz","year":"2010","journal-title":"Am J Addict"},{"key":"R19-2-20210129","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/add.12208","article-title":"Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.","volume":"108","author":"Krupitsky","year":"2013","journal-title":"Addiction"},{"key":"R20-2-20210129","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0306-4522(02)00073-8","article-title":"Regulation of mu-opioid receptors, G-protein-coupled receptor kinases and beta-arrestin 2 in the rat brain after chronic opioid receptor antagonism.","volume":"112","author":"Diaz","year":"2002","journal-title":"Neuroscience"},{"key":"R21-2-20210129","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","article-title":"Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs.","volume":"59","author":"Volpe","year":"2011","journal-title":"Regul Toxicol Pharmacol"},{"key":"R22-2-20210129","doi-asserted-by":"crossref","first-page":"9156","DOI":"10.1021\/jm4012214","article-title":"Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mukappa opioid receptor dual selectivity.","volume":"56","author":"Yuan","year":"2013","journal-title":"J Med Chem"},{"key":"R23-2-20210129","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"R24-2-20210129","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.","volume":"349","author":"Fudala","year":"2003","journal-title":"N Engl J Med"},{"key":"R25-2-20210129","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"R26-2-20210129","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.2008.574","article-title":"Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.","volume":"300","author":"Woody","year":"2008","journal-title":"JAMA"},{"issue":"3","key":"R27-2-20210129","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R28-2-20210129","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/09595230701373834","article-title":"Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records.","volume":"26","author":"Gibson","year":"2007","journal-title":"Drug Alcohol Rev"},{"key":"R29-2-20210129","first-page":"503","article-title":"Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness Am J Drug Alcohol A","volume":"32","author":"Nunes","year":"2006","journal-title":"buse"},{"key":"R30-2-20210129","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1360-0443.2012.03910.x","article-title":"Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use.","volume":"107","author":"Kelty","year":"2012","journal-title":"Addiction"},{"key":"R33-2-20210129","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/dar.12095","article-title":"A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence.","volume":"33","author":"Larney","year":"2014","journal-title":"Drug Alcohol Rev"},{"key":"R34-2-20210129","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1001\/jama.2010.1427","article-title":"Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.","volume":"304","author":"Ling","year":"2010","journal-title":"JAMA"},{"key":"R35-2-20210129","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R36-2-20210129","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.drugalcdep.2011.06.023","article-title":"Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.","volume":"120","author":"DeFulio","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"R37-2-20210129","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/j.1360-0443.2011.03400.x","article-title":"Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial.","volume":"106","author":"Everly","year":"2011","journal-title":"Addiction"},{"key":"R38-2-20210129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bph.12600","article-title":"Novel GPCR paradigms at the mu-opioid receptor.","volume":"172","author":"Thompson","year":"2015","journal-title":"Br J Pharmacol"},{"key":"R39-2-20210129","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/pr.112.005942","article-title":"Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol Rev"},{"key":"R40-2-20210129","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1523\/JNEUROSCI.4187-12.2013","article-title":"Increased agonist affinity at the mu-opioid receptor induced by prolonged agonist exposure.","volume":"33","author":"Birdsong","year":"2013","journal-title":"J Neurosci"},{"key":"R42-2-20210129","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2217\/pgs.13.57","article-title":"OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis.","volume":"14","author":"Haerian","year":"2013","journal-title":"Pharmacogenomics"},{"key":"R43-2-20210129","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.drugalcdep.2011.10.031","article-title":"Examining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: from a symposium on new concepts in mu-opioid pharmacology.","volume":"121","author":"Whistler","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"R44-2-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00213-006-0365-8","article-title":"Development of tolerance and sensitization to different opioid agonists in rats.","volume":"186","author":"Grecksch","year":"2006","journal-title":"Psychopharmacology"},{"key":"R45-2-20210129","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2217\/pgs.13.13","article-title":"Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg.","volume":"14","author":"Hajj","year":"2013","journal-title":"Pharmacogenomics"},{"key":"R46-2-20210129","doi-asserted-by":"crossref","first-page":"e86114","DOI":"10.1371\/journal.pone.0086114","article-title":"Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis.","volume":"9","author":"Dennis","year":"2014","journal-title":"PLoS One"},{"key":"R48-2-20210129","first-page":"588","article-title":"Methadone maintenance in the treatment of opioid dependence. A current perspective.","volume":"152","author":"Zweben","year":"1990","journal-title":"West J Med"},{"key":"R49-2-20210129","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphinenaloxone compared to methadone in a multi-site trial.","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"key":"R50-2-20210129","first-page":"CD006318","article-title":"Maintenance agonist treatments for opiate-dependent pregnant women.","volume":"12","author":"Minozzi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R51-2-20210129","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/QAI.0000000000000165","article-title":"HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial.","volume":"66","author":"Woody","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R52-2-20210129","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1365-2362.2003.01218.x","article-title":"Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study.","volume":"33","author":"Ahmadi","year":"2003","journal-title":"Eur J Clin Invest"},{"issue":"8","key":"R53-2-20210129","first-page":"CD004145","article-title":"Oral substitution treatment of injecting opioid users for prevention of HIV infection.","author":"Gowing","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"R54-2-20210129","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.drugalcdep.2014.03.006","article-title":"The impact of buprenorphinenaloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients.","volume":"139","author":"Edelman","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"R55-2-20210129","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.drugalcdep.2013.06.024","article-title":"Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavioroutcomes of a randomized trial.","volume":"133","author":"Otiashvili","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"R56-2-20210129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/QAI.0b013e3181d916db","article-title":"HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study.","volume":"55","author":"Meade","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R57-2-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","article-title":"Buprenorphinenaloxone and methadone effects on laboratory indices of liver health: a randomized trial.","volume":"128","author":"Saxon","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"R58-2-20210129","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/aje\/kwn237","article-title":"Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place.","volume":"168","author":"Hagan","year":"2008","journal-title":"Am J Epidemiol"},{"key":"R59-2-20210129","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1360-0443.2011.03765.x","article-title":"Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment.","volume":"107","author":"Pouget","year":"2012","journal-title":"Addiction"},{"key":"R60-2-20210129","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jvh.12117","article-title":"Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data.","volume":"21","author":"Palmateer","year":"2014","journal-title":"J Viral Hepat"},{"key":"R61-2-20210129","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/add.12682","article-title":"The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users.","volume":"109","author":"Nolan","year":"2014","journal-title":"Addiction"},{"key":"R62-2-20210129","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1001\/jamainternmed.2014.5416","article-title":"Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.","volume":"174","author":"Tsui","year":"2014","journal-title":"JAMA Intern Med"},{"key":"R63-2-20210129","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/dar.12143","article-title":"Opioid-related mortality and filled prescriptions for buprenorphine and methadone.","volume":"33","author":"Wikner","year":"2014","journal-title":"Drug Alcohol Rev"},{"key":"R64-2-20210129","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/jamainternmed.2013.12711","article-title":"High-risk use by patients prescribed opioids for pain and its role in overdose deaths.","volume":"174","author":"Baumblatt","year":"2014","journal-title":"JAMA Intern Med"},{"key":"R65-2-20210129","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jpain.2014.01.495","article-title":"Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline.","volume":"15","author":"Chou","year":"2014","journal-title":"J Pain"},{"key":"R66-2-20210129","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.drugpo.2014.03.014","article-title":"Timing of income assistance payment and overdose patterns at a Canadian supervised injection facility.","volume":"25","author":"Zlotorzynska","year":"2014","journal-title":"Int J Drug Policy"},{"key":"R67-2-20210129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/dar.12108","article-title":"Opioid overdose and the power of old myths: what we thought we knew, what we do know and why it matters.","volume":"33","author":"Darke","year":"2014","journal-title":"Drug Alcohol Rev"},{"key":"R68-2-20210129","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jsat.2012.07.004","article-title":"Opioid overdose prevention with intranasal naloxone among people who take methadone.","volume":"44","author":"Walley","year":"2013","journal-title":"J Subst Abuse Treat"},{"key":"R69-2-20210129","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1046\/j.1360-0443.1999.9479612.x","article-title":"Mechanisms of fatal opioid overdose.","volume":"94","author":"White","year":"1999","journal-title":"Addiction"},{"key":"R70-2-20210129","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/pme.12480","article-title":"Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients.","volume":"15","author":"Zedler","year":"2014","journal-title":"Pain Med"},{"key":"R71-2-20210129","doi-asserted-by":"crossref","first-page":"e60600","DOI":"10.1371\/journal.pone.0060600","article-title":"Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada.","volume":"8","author":"Madadi","year":"2013","journal-title":"PLoS One"},{"key":"R72-2-20210129","first-page":"101","article-title":"Community-based opioid overdose prevention programs providing naloxoneUnited States, 2010.","volume":"61","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R73-2-20210129","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1046\/j.1440-1614.2002.01012.x","article-title":"Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose.","volume":"36","author":"Ritter","year":"2002","journal-title":"Aust N Z J Psychiatry"},{"key":"R74-2-20210129","doi-asserted-by":"crossref","first-page":"991","DOI":"10.15288\/jsad.2012.73.991","article-title":"Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection.","volume":"73","author":"Mitchell","year":"2012","journal-title":"J Stud Alcohol Drugs"},{"key":"R75-2-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1360-0443.2012.04043.x","article-title":"Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication.","volume":"1","author":"McNicholas","year":"2012","journal-title":"Addiction"},{"key":"R76-2-20210129","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/ADM.0b013e3181c4e27e","article-title":"Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults.","volume":"4","author":"Bogenschutz","year":"2010","journal-title":"J Addict Med"},{"key":"R77-2-20210129","first-page":"S24","article-title":"Evaluation of the profile of patients with QTc prolongation in spontaneous adverse event reporting over the past three decades1969-1998.","volume":"9","author":"Fung","year":"2000","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R78-2-20210129","first-page":"CD008939","article-title":"QTc interval screening for cardiac risk in methadone treatment of opioid dependence.","volume":"6","author":"Pani","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R79-2-20210129","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.drugalcdep.2007.05.019","article-title":"Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients.","volume":"91","author":"Lintzeris","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"R80-2-20210129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.toxlet.2014.04.009","article-title":"Respiratory effects of buprenorphinenaloxone alone and in combination with diazepam in naive and tolerant rats.","volume":"228","author":"Cohier","year":"2014","journal-title":"Toxicol Lett"},{"key":"R81-2-20210129","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/01.jcp.0000219050.33008.61","article-title":"Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients.","volume":"26","author":"Lintzeris","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R82-2-20210129","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.drugalcdep.2011.04.013","article-title":"Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients.","volume":"118","author":"McCance-Katz","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"R83-2-20210129","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.drugalcdep.2007.06.007","article-title":"Interaction between buprenorphine and atazanavir or atazanavirritonavir.","volume":"91","author":"McCance-Katz","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"R84-2-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00952990.2010.540279","article-title":"Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence.","volume":"37","author":"Saber-Tehrani","year":"2011","journal-title":"Am J Drug Alcohol Abuse"},{"key":"R85-2-20210129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1360-0443.2012.04035.x","article-title":"Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.","volume":"1","author":"Jones","year":"2012","journal-title":"Addiction"},{"key":"R86-2-20210129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/0890334413517748","article-title":"The wellbeing of infants exposed to buprenorphine via breast milk at 4 weeks of age.","volume":"30","author":"Gower","year":"2014","journal-title":"J Hum Lact"},{"key":"R87-2-20210129","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/1552-6909.12242","article-title":"Breastfeeding promotion for management of neonatal abstinence syndrome.","volume":"42","author":"Pritham","year":"2013","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"key":"R88-2-20210129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1360-0443.2012.04039.x","article-title":"Differences in the profile of neonatal abstinence syndrome signs in methadone-versus buprenorphine-exposed neonates.","volume":"1","author":"Gaalema","year":"2012","journal-title":"Addiction"},{"key":"R89-2-20210129","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1360-0443.2012.04037.x","article-title":"Fetal assessment before and after dosing with buprenorphine or methadone.","volume":"1","author":"Salisbury","year":"2012","journal-title":"Addiction"},{"key":"R90-2-20210129","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1360-0443.2012.04040.x","article-title":"Neonatal neurobehavior effects following buprenorphine versus methadone exposure.","volume":"1","author":"Coyle","year":"2012","journal-title":"Addiction"},{"key":"R91-2-20210129","first-page":"271","article-title":"Developmental outcome of children born to methadone maintained women: a review of longitudinal studies.","volume":"6","author":"Kaltenbach","year":"1984","journal-title":"Neurobehav Toxicol Teratol"},{"key":"R92-2-20210129","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1360-0443.2009.02627.x","article-title":"Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.","volume":"104","author":"Bell","year":"2009","journal-title":"Addiction"},{"key":"R93-2-20210129","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/00952990.2011.653426","article-title":"Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.","volume":"38","author":"Sigmon","year":"2012","journal-title":"Am J Drug Alcohol Abuse"},{"key":"R94-2-20210129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.drugalcdep.2013.12.005","article-title":"The diversion and injection of a buprenorphine-naloxone soluble film formulation.","volume":"136","author":"Larance","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"R95-2-20210129","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1521-0391.2013.12024.x","article-title":"Clinician beliefs and attitudes about buprenorphinenaloxone diversion.","volume":"22","author":"Schuman-Olivier","year":"2013","journal-title":"Am J Addict"},{"key":"R96-2-20210129","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1097\/PCC.0b013e3181f3a118","article-title":"Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphinenaloxone.","volume":"12","author":"Pedapati","year":"2011","journal-title":"Pediatr Crit Care Med"},{"key":"R97-2-20210129","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/fampra\/18.5.545","article-title":"Residential rehabilitation for drug users: a review of 13 months intake to a therapeutic community.","volume":"18","author":"Keen","year":"2001","journal-title":"Fam Pract"},{"key":"R98-2-20210129","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1176\/appi.ajp.159.1.22","article-title":"The Lexington narcotic farm.","volume":"159","author":"Kosten","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R99-2-20210129","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1521-0391.2013.00317.x","article-title":"Predictors of dropout from psychosocial treatment in opioid-dependent outpatients.","volume":"22","author":"McHugh","year":"2013","journal-title":"Am J Addict"},{"key":"R100-2-20210129","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.addbeh.2012.04.011","article-title":"Predictors of attrition with buprenorphinenaloxone treatment in opioid dependent youth.","volume":"37","author":"Warden","year":"2012","journal-title":"Addict Behav"},{"issue":"1","key":"R101-2-20210129","first-page":"CD004330","article-title":"Psychosocial treatment for opiate abuse and dependence.","author":"Mayet","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"R102-2-20210129","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1360-0443.2004.00728.x","article-title":"Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification.","volume":"99","author":"Masson","year":"2004","journal-title":"Addiction"},{"key":"R103-2-20210129","first-page":"62","article-title":"Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored.","volume":"68","author":"Magura","year":"2001","journal-title":"Mt Sinai J Med"},{"key":"R104-2-20210129","first-page":"7","article-title":"Opioids and traffic safetyfocus on buprenorphine.","volume":"47","author":"Soyka","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"R105-2-20210129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1472-6904-11-13","article-title":"Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates.","volume":"11","author":"Rapeli","year":"2011","journal-title":"BMC Clin Pharmacol"},{"key":"R106-2-20210129","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"key":"R107-2-20210129","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/jcp.0b013e31814ce50d","article-title":"Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.","volume":"27","author":"OMalley","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R108-2-20210129","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/1475-6773.12093","article-title":"Adoption and diffusion of evidence-based addiction medications in substance abuse treatment.","volume":"49","author":"Heinrich","year":"2014","journal-title":"Health Serv Res"},{"key":"R109-2-20210129","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1747-597X-8-35","article-title":"Qualitative investigation of barriers to accessing care by people who inject drugs in Saskatoon, Canada: perspectives of service providers.","volume":"8","author":"Lang","year":"2013","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"R110-2-20210129","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1001\/jama.286.14.1724","article-title":"Methadone maintenance in primary care: a randomized controlled trial.","volume":"286","author":"Fiellin","year":"2001","journal-title":"JAMA"},{"key":"R111-2-20210129","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/1471-2458-12-488","article-title":"Methadone induction in primary care (ANRS-Methaville): a phase III randomized intervention trial.","volume":"12","author":"Roux","year":"2012","journal-title":"BMC Public Health"},{"key":"R112-2-20210129","first-page":"1108","article-title":"Short-term outcomes in patients attending a primary care-based addiction shared care program.","volume":"55","author":"Kahan","year":"2009","journal-title":"Can Fam Physician"},{"key":"R113-2-20210129","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1521-0391.2012.12005.x","article-title":"Buprenorphine naloxone in the treatment of opioid dependence during pregnancyinitial patient care and outcome data.","volume":"22","author":"Debelak","year":"2013","journal-title":"Am J Addict"},{"key":"R115-2-20210129","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/10550887.2012.759872","article-title":"A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.","volume":"32","author":"Neumann","year":"2013","journal-title":"J Addict Dis"},{"key":"R116-2-20210129","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/00952990902933878","article-title":"Time-dependent neuroendocrine alterations and drug craving during the first month of abstinence in heroin addicts.","volume":"35","author":"Shi","year":"2009","journal-title":"Am J Drug Alcohol Abuse"},{"key":"R117-2-20210129","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.biopsych.2008.11.025","article-title":"Circadian alteration in neurobiology during 30 days of abstinence in heroin users.","volume":"65","author":"Li","year":"2009","journal-title":"Biol Psychiatry"},{"key":"R118-2-20210129","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/archpsyc.62.10.1157","article-title":"Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.","volume":"62","author":"Marsch","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R119-2-20210129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fphar.2014.00116","article-title":"Its MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system.","volume":"5","author":"Chartoff","year":"2014","journal-title":"Front Pharmacol"},{"key":"R120-2-20210129","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1037\/a0033724","article-title":"Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.","volume":"21","author":"Sanders","year":"2013","journal-title":"Exp Clin Psychopharmacol"},{"key":"R121-2-20210129","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jsat.2014.01.005","article-title":"A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.","volume":"46","author":"Bisaga","year":"2014","journal-title":"J Subst Abuse Treat"},{"key":"R122-2-20210129","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.drugalcdep.2011.05.019","article-title":"A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence.","volume":"119","author":"Bisaga","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"R123-2-20210129","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/ptr.5073","article-title":"Phytotherapy of opioid dependence and withdrawal syndrome: a review.","volume":"28","author":"Tabatabai","year":"2014","journal-title":"Phytother Res"},{"key":"R124-2-20210129","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/1472-6882-14-308","article-title":"An-jun-ning, a traditional herbal formula, attenuates spontaneous withdrawal symptoms via modulation of the dopamine system in morphine-dependent rats.","volume":"14","author":"Gao","year":"2014","journal-title":"BMC Complement Altern Med"}],"container-title":["Harvard Review of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HRP.0000000000000075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:44:51Z","timestamp":1620953091000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00023727-201503000-00002"}},"subtitle":["Review of the Evidence and Future Directions"],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/hrp.0000000000000075","relation":{},"ISSN":["1067-3229"],"issn-type":[{"value":"1067-3229","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}